# The comparative effectiveness and safety of biologic therapies for uncontrolled severe asthma: a systematic review and network meta-analysis

Tyler Pitre
  *Department of Medicine*
  *McMaster University, Hamilton, ON*

Tanvir Jassal (tanvirjassal@hotmail.com)
  *Department of Anesthesia*
  *McMaster University, Hamilton, ON*

Albi Angjeli (angjelia@mcmaster.ca)
  *Faculty of Health Sciences*
  *McMaster University, Hamilton, ON*

Vineeth Jarabana (vineethjarabana@gmail.com)f
  *Faculty of Health Sciences*
  *Queens University, Hamilton, ON*

Sricherry Nannapaneni (sricherrynannapaneni@gmail.com)
  *Faculty of Health Sciences*
  *McMaster University, Hamilton, ON*

Ayesha Umair (umaira1@mcmaster.ca)
  *Faculty of Health Sciences*
  *McMaster University, Hamilton, ON*

Muizz Hussain (muizz.hussain@medportal.ca)
  *Michael G. DeGroote School of Medicine*
  *McMaster University, Hamilton, ON*

Gareth Leung (gareth.k.leung@gmail.com)
  *Faculty of Medicine,*
  *University of Ottawa, Ottawa, ON*

Sarah Kirsch (sarahkirsh@hotmail.com)
  *Department of Anesthesia*
  *McMaster University, Hamilton, ON*

Johnny Su (johnny.su@medportal.ca)
  *Department of Medicine*
  *McMaster University, Hamilton, ON*

Kairavi Desai (kairavi.desai@medportal.ca)
  *Michael G. DeGroote School of Medicine*
  *McMaster University, Hamilton, ON*

Dena Zeraatkar*
  *Department of Health Research Methods, Evidence, and Impact*
  *McMaster University, Hamilton, ON*

*Corresponding author: dena.zera@gmail.com; Department of Health Research Methods, Evidence, and

Impact, McMaster University, Hamilton, ON

**Running head:** Biologics for asthma

**Disclaimers/Conflicts of interest:** None

**Funding**: DZ is funded by a Banting postdoctoral fellowship.

**Data:** Data will be available on OSF upon publication.

**Acknowledgements:** None

**Authors' Contributions:** TP and DZ conceived the study. TJ, AA, VJ, SN, AU, MH, GL, SK, JS, KD, and TP

screened and extracted data. DZ and TP performed the analysis and GRADED the certainty of the

evidence. TP drafted the manuscript and all authors reviewed and provided intellectual input.

**Keywords:** asthma, biologics, systematic review, network meta-analysis

**Word count:** 3,606

**Abstract**

**Background:** To date, no trial has directly compared biologics for the treatment of uncontrolled severe

asthma and the choice of biologic has been largely guided by biological and practical considerations,

such as inflammatory biomarkers, blood and sputum eosinophils, and access and payer coverage.

**Study design:** Systematic review and network meta-analysis

**Methods:** We searched MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov from inception to May 31,

2022 for randomized trials addressing biologic therapies for asthma. Reviewers worked independently

and in duplicate to screen references, extract data, and assess risk of bias. We performed a frequentist

network meta-analysis and assessed the certainty (quality) of evidence using the GRADE approach. We

present data as absolute risk difference per 1000 patients with 95% confidence intervals (95% CI) and

continuous outcomes as mean difference (MD) and 95% CI.

**Results:** We identified 63 eligible trials, including 26,320 patients. For patients with eosinophilic asthma,

tezepelumab (329 fewer exacerbations per 1000 [95% CI 272.6 to 366.6 fewer]) and dupilumab (319.6

fewer exacerbations per 1000 [95% CI 272.6 to 357.2 fewer]) reduce exacerbations compared to placebo

(high certainty). Tezepelumab (MD 0.24 L [95% CI 0.16 to 0.32]) and dupilumab (0.25 L (95% CI 0.21 to

0.29) improve lung function (FEV1) compared to placebo (high certainty). Both tezepelumab (110.97

fewer hospital admissions per 1000 (95% CI 94.53 to 120.56 fewer) and dupilumab (97.27 fewer

hospitalizations [4.11 to 124.67 fewer]) probably reduce hospital admissions compared to placebo

(moderate certainty). For patients with low eosinophils, biologics probably do not improve asthma

outcomes. For these patients, tezepelumab (MD 0.1 L [95% CI 0 to 0.19]) and dupilumab (MD 0.1 L [95%

CI 0 to 0.20)] may improve lung function (low certainty). None of the biologics increased adverse events

leading to discontinuation (high certainty).

**Conclusion:** For patients with eosinophilic asthma, tezepelumab and dupilumab are effective at reducing

exacerbations, without important differences in the effects of these biologics. For patients with low

eosinophils, however, biologics, including tezepelumab, probably do not prevent exacerbations, improve

asthma control, or lung function.

## Background

Asthma is a respiratory condition that affects an estimated 300 million people and is associated with significant morbidity (1). Patients whose asthma cannot be controlled by inhaled corticosteroids and long-acting β2-agonists and patients who rely on oral corticosteroids may benefit from biologics (2). Biologics target the signalling pathways involved in inflammation, which play an important role in the pathogenesis of asthma.

To date, no trial has directly compared biologics for the treatment of uncontrolled severe asthma and the choice of biologic has been largely guided by biological and practical considerations, such as inflammatory biomarkers, blood and sputum eosinophils, and access and payer coverage. Additionally, the optimal biologic for patients who qualify for more than one option and the order in which clinicians should trial biologics for patients are unclear (3). Furthermore, access to most biologics has been limited to patients with specific phenotypes (e.g., high eosinophilic asthma). The emergence of anti-alarmins— treatments that should theoretically be effective regardless of eosinophil levels—further necessitates additional evidence to help select optimal biologics for patients (4).

To address these challenges, we present a systematic review and network meta-analysis comparing biologics for severe uncontrolled asthma. A network meta-analysis pools results across two or more studies and, unlike a traditional pairwise meta-analysis, facilitates comparisons of three or more interventions simultaneously (5). A network meta-analysis can also yield more precise estimates than a traditional pairwise meta-analysis and can facilitate comparison of interventions that have not been directly compared against each other.

## Methods

We registered our protocol on Open Science Framework (https://osf.io/m29du/) on June 14, 2022. We report our results using the PRISMA-NMA extension (6).

### Search strategy

In consultation with an experienced research librarian, we searched MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov from inception to May 31, 2022, for randomized trials addressing biologic therapies for asthma. We did not restrict the search by language or date of publication. We supplemented our search by reviewing references of similar systematic reviews (7-11). Supplement 1 presents our full search strategy.

*Screening*

Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working independently and in duplicate, reviewed titles and abstracts of search results and subsequently the full-texts of records deemed potentially eligible at the title and abstract screening stage.

We included trials that randomized adults with severe asthma to one or more biologic therapies with standard care, placebo, or other biologic therapies, regardless of language or date of publication. We included trials that recruited both children and adults if 80% or more patients were adults (>18 years). We excluded trials that reported on the effects of aerosolized or nebulized biologics or trials that included fewer than 10 participants in each arm.

Reviewers resolved discrepancies by discussion, or, when necessary, by adjudication with a third party.

*Data extraction*

Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working independently and in duplicate, extracted data from eligible studies. We extracted data on trial characteristics (e.g., country of recruitment), patient characteristics (e.g., age, eosinophil levels), intervention characteristics (e.g., dose and duration), and outcomes. The coreASTHMA core outcome set—a multistakeholder core outcome set for asthma—informed our outcomes of interest (12), which include exacerbations, asthma control as measured by the Asthma Control Questionnaire, lung function measured by prebronchodilator forced expiratory volume in 1 second (FEV1), hospitalizations, reduction in use of systemic corticosteroids by ≥50%, and adverse events leading to discontinuation.

We anticipated that the effects of biologics on exacerbations, asthma control, and lung function may differ according to baseline eosinophil count. To facilitate subgroup analyses, we extracted subgroup data based on baseline blood and sputum eosinophil count, when reported. We classified trials as reporting on eosinophilic asthma when 80% or more of patients had blood eosinophils of ≥300 eosinophils per μL in the past year, ≥150 eosinophils per μL in the trial screening period, or sputum eosinophils ≥3%.

Reviewers resolved discrepancies by discussion or, when necessary, by adjudication with a third party.

*Risk of bias assessments*

Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working independently and in duplicate, assessed the risk of bias of trials using a modification of the Cochrane-endorsed RoB 2.0 tool (13, 14). We rated each outcome as either at (1) low risk of bias, (2) probably low

risk of bias, (3) probably high risk of bias or (4) high risk of bias, across the following domains: bias

arising from the randomisation process; bias owing to departures from the intended intervention; bias

from missing outcome data; bias in measurement of the outcome; bias in selection of the reported

results. Trials were rated at high risk of bias overall if one or more domains were rated at probably high

or high risk of bias. Reviewers resolved discrepancies by discussion and, when not possible, with

adjudication by a third party. Supplement 2 presents the modified risk of bias tool.

***Data analysis***

We present the results of dichotomous outcomes as relative risks (RRs) and continuous outcomes as

mean differences (MDs), with associated 95% confidence intervals (95% CIs). To facilitate interpretation,

for dichotomous outcomes, we calculate absolute effects expressed as events per 1,000 patients, using

the median risk in the placebo arms as the assumed baseline risk without biologics.

For each outcome, we performed frequentist random-effects network meta-analysis using the restricted

maximum likelihood (REML) estimator. We categorized each biologic drug as a separate node in the

network. We anticipated that the effects of biologic therapies on exacerbations, asthma control, and

lung function may differ based on baseline eosinophil count. For these outcomes, we performed three

analyses: one restricted to patients with high eosinophils, one restricted to patients with low

eosinophils, and one including all patients.

We summarize heterogeneity using the $I^2$ statistic. We considered heterogeneity ranging from 0%–40%

as potentially unimportant, 30%–60% as moderate, 50%–90% as substantial and 75%–100% as critical

(15). We used the node-splitting method to test for local incoherence (difference between direct and

indirect evidence in closed loops) (16). For analyses with 10 or more trials, we assessed for publication

bias using comparison-adjusted funnel plots and the Egger's test (17).

We performed meta-analyses using meta and netmeta packages in R v. 4.1.2 (Vienna, Austria) and we

used the networkplot command in Stata v.17 (StataCorp) to generate network plots (18-20).

***Evaluation of the certainty (quality) of evidence***

Reviewers, working independently and in duplicate, assessed the certainty (quality) of evidence using

the GRADE approach for network meta-analysis (21-23). Reviewers resolved discrepancies by discussion

or by adjudication by a third reviewer.

For each comparison and for each outcome, we rated the certainty of evidence as either high,

moderate, low, or very low based on considerations of risk of bias (i.e., study limitations), inconsistency

(i.e., heterogeneity in trial results), indirectness (i.e., differences between the questions addressed in

trials and the question of interest), publication bias (i.e., the tendency for trials with statistically

significant results or positive results to be published, published faster, or published in journals with

higher visibility), intransitivity (i.e., differences in trial characteristics across the network), incoherence

(i.e., difference between direct and indirect effects), and imprecision (i.e., random error). High certainty

evidence indicates situations in which we are confident that the estimated effect represents the true

effect and low or very low certainty evidence indicates situations in which the estimated effect may be

substantially different from the true effect.

We made judgements about imprecision using the minimally contextualized GRADE approach (23). This

approach does not consider statistical significance as the only indicator of whether an intervention is

effective. An estimate may not be statistically significant but may still have evidence of moderate

certainty for benefit or harm, depending on the width of the confidence intervals and whether they

cross the thresholds of clinical significance. Conversely, an intervention may produce results that are

statistically significant but that indicate no important benefit or harm (e.g., a 10 mL change in FEV1). A

minimally contextualized approach considers whether confidence intervals include the minimally

important difference (the smallest change in the outcome considered to be important to patients) and

does not consider whether it includes both minimally important and large effects.

We sourced minimally important differences from the literature or by consensus of the authors. We

considered a 20% reduction in risk of exacerbations (24, 25), 0.5 reduction in the Asthma Control

Questionnaire (25), 100 mL reduction in FEV1 (24, 26), 5% reduction in risk of hospital admissions, 20%

increase in risk of reducing oral corticosteroids by ≥50%, and a 10% increase in risk of adverse events

leading to discontinuation to be minimally important.

We report our results using guidance from the GRADE Working Group, which involves describing the

effect of an intervention based on the certainty of evidence (i.e., high certainty evidence the drug is

effective, moderate certainty evidence the drug is probably effective, low certainty evidence the drug

may be effective and very low certainty evidence the effect of the drug is unclear) (27).

**Results**

*Search results*

Our search yielded 3,225 unique references. We identified a total of 57 eligible publications reporting on

63 unique trials with 26,320 patients (28-81). All trials were published in peer-reviewed journals in

English. Supplement 3 presents additional details related to study selection.

*Trial and participant characteristics*

Table 1 presents trial and participant characteristics. Sixteen trials (4,730 patients) reported on

omalizumab, eight (4,511 patients) on fevipiprant, seven (2,511 patients) on reslizumab, six (1,966

patients) on mepolizumab, four (2,312 patients) on tralokinumab, four (1,799 patients) on tezepelumab,

three (1,090 patients) on dupilumab, three (1,417 patients) on benralizumab, one (375 patients) on

astegolimab, and one (296 patients) on itepekimab.

Trials typically recruited adult asthmatic patients with a history of one or more exacerbations in the last

year despite treatment with medium-dose to high-dose inhaled corticosteroids and another asthma

controller (e.g., oral corticosteroids, long-acting β2-agonists).

Twelve trials (3,870 patients) recruited patients with high eosinophils (blood eosinophils of ≥300

eosinophils per µL in the past year, ≥150 eosinophils per µL in the trial screening period, or sputum

eosinophils ≥3%) and 51 trials (22,432 patients) recruited patients with both low and high eosinophils.

Among trials that recruited patients with both low and high eosinophils, 19 (13,592 patients) reported

subgroup analyses based on eosinophil levels for one or more of our outcomes of interest.

*Risk of bias*

Supplement 4 presents risk of bias assessments. We judged two trials to be at high risk of bias due to

their open-label design and inadequate description of allocation concealment. We judged all other

outcomes to be at low risk of bias. Pharmaceutical companies funded all trials.

*Exacerbations*

Table 2 and supplement 5 present results with associated GRADE ratings. Forty-two trials, including

20,964 patients, reported exacerbations. Of these, twenty-seven trials reported on 10,159 patients with

high eosinophils and thirteen trials reported 4,628 patients with low eosinophils. Figure 1 presents the

geometry of the networks and figure 2 presents the network forest plot.

For patients with eosinophilic asthma (>=300 cells/uL), we found moderate to high certainty evidence

that benralizumab (RR 0.51 [95% CI 0.41 to 0.63]), dupilumab (RR 0.32 [95% 0.24 to 0.42,]) mepolizumab

(RR 0.52 [95% CI 0.43 to 0.64]), reslizumab (RR 0.51 [95% CI 0.4 to 0.65]), and tezepelumab (RR 0.3 [0.22

to 0.42]) probably reduce exacerbations compared to placebo. We did not find moderate or high

certainty evidence that either of these drugs are superior to each other.

For patients with low eosinophils (< 300 cells/uL), we did not find moderate or high certainty evidence

that any of the drugs reduce exacerbations (i.e., none met the pre-specified minimally important

difference of 20%).

For all patients, omalizumab, astegolimab, and tralokinumab probably do not reduce exacerbations as

compared to placebo.

Supplement 6 and 7 presents the network geometries, forest plots, and heterogeneity statistics.

***Asthma control (Asthma Control Questionnaire)***

Thirty-six trials, including 12,161 patients, reported on asthma control using the asthma control

questionnaire (82). Of these, ten trials reported on 8,212 patients with high eosinophils and eight trials

reported on 1,905 patients with low eosinophils. Supplement 6 and 7 presents the network geometries,

forest plots, and heterogeneity statistics.

For patients with eosinophilic asthma, we found low certainty evidence that dupilumab may improve

asthma control compared to placebo (MD -0.73 [95% CI -0.98 to -0.48]). We did not find moderate or

high certainty evidence that any of the biologics improve asthma control for this population.

For patients with low eosinophils, we found moderate to high certainty evidence that benralizumab (MD

-0.23 [95% CI -0.41 to -0.06]), dupilumab (MD -0.2 [95% -0.42 to 0.02]), reslizumab (MD 0.12 [95% CI -

0.09 to 0.33]), and tezepelumab (MD -0.23 [95% CI -0.36 to -0.09]) probably do not improve asthma

control compared to placebo.

***Lung function (FEV1)***

Forty-two trials, including 17,965 patients, reported lung function. Of these, twenty-nine trials reported

on 9,242 patients with high eosinophils and twelve trials reported on 2745 patients with low

eosinophils. Supplement 6 and 7 presents the network geometries, forest plots, and heterogeneity

statistics.

For patients with high eosinophils, we found moderate to high certainty evidence that dupilumab (MD

0.25 L [95% CI 0.21 to 0.29]), reslizumab (MD 0.19 L [95% CI 0.12 to 0.25]), and tezepelumab (MD 0.24 L

[0.16 to 0.32]) probably improve lung function compared to placebo. We found moderate certainty

evidence that dupilumab is probably superior to benralizumab (MD 0.11 L [95% CI 0.05 to 0.16])  and

mepolizumab (MD 0.15 L [95% CI 0.08 to 0.22]) for improving lung function and that tezepelumab is

probably superior to mepolizumab (MD 0.15 L [95% CI 0.05 to 0.24]). We found moderate certainty

evidence that dupilumab and tezepelumab probably improve lung function equally well (MD 0.01 L [95%

CI -0.08 to 0.1]).

For patients with low eosinophils, we did not find moderate or high certainty evidence that any biologics

improve lung function.

***Hospital admissions***

Thirteen trials, including 3,113 patients, reported on hospital admission. Supplement 6 and 7 presents

the network geometry, forest plot, and heterogeneity statistics.

We found moderate certainty evidence that mepolizumab (RR 0.29 [95% CI 0.09 to 0.97]), omalizumab

(RR 0.38 [95% CI 0.23 to 0.65]), and tezepelumab (RR 0.19 [95% CI [0.12 to 0.31]) probably reduce

hospital admissions compared to placebo. We found moderate to high certainty evidence that

omalizumab is probably superior to benralizumab (RR 0.44 [95% CI 0.25 to 0.78]) and tralokinumab (RR

0.5 [95% CI 0.27 to 0.95]) for reducing hospital admissions. We found moderate certainty evidence that

tezepelumab is probably superior to benralizumab for reducing hospitalizations (RR 0.22 [95% CI 0.13 to

0.37]).

***Reduction in use of oral corticosteroids (≥50% reduction in oral corticosteroids)***

Six trials, including 4849 patients, reported ≥50% reduction in oral corticosteroids. Supplement 6 and 7

presents the network geometry, forest plots, and heterogeneity statistics.

We found moderate certainty evidence that benralizumab (RR 1.77 [95% CI 1.29 to 2.43]), dupilumab

(RR 1.49 [95% CI 1.22 to 1.83], and mepolizumab [RR 1.61 [95% CI 1.07 to 2.41]) probably reduce use of

oral corticosteroids compared to placebo. We did not find moderate or high certainty evidence that

either of these drugs are superior to each other.

***Adverse events leading to discontinuation***

Forty-seven trials, including 8,781 patients, reported adverse events leading to discontinuation.

Supplement 6 and 7 presents the network geometry, forest plots, and heterogeneity statistics.

We have moderate to high certainty evidence that benralizumab (RR 1.65 [95% CI 0.79 to 3.45]),

dupilumab (RR 1.03 [95% CI 0.46 to 2.3]), fevipiprant (RR 1.01 [95% CI 0.65 to 1.57]), mepolizumab [RR

0.65 [95% CI 0.36 to 1.16]), omalizumab (RR 1.2 [95% CI 0.80 to 1.81]), reslizumab (RR 0.65 [0.41 to

1.02]), tezepelumab (RR 0.68 [95% CI 0.0.34 to 1.35]), and tralokinumab (RR 2.7 [95% CI 1.45 to 5])

probably do not increase the risk adverse events compared to placebo.

**Discussion**

*Main findings*

Our systematic review and network meta-analysis presents data from 63 trials addressing the

effectiveness and safety of biologics for uncontrolled severe asthma. We show that for patients with

eosinophilic asthma, tezepelumab and dupilumab are the most effective at reducing asthma

exacerbations and lung function. We did not find moderate or high certainty evidence that either of

these drugs are superior to each other.

Contrary to expectations, for patients with low eosinophils, biologics, including tezepelumab that has

been marketed as effective even in patients with low eosinophils (83), probably do not prevent

exacerbations or improve asthma control or lung function.

*Strengths and limitation*

The strengths of this review include our comprehensive search for trials addressing biologics for asthma,

duplicate screening and data extraction, and rigorous evaluation of the certainty of evidence. We

considered the potential differential effects of biologics based on eosinophil counts, which play a key

role in the pathogenesis of severe asthma. We focused on patient-important outcomes and our choice

of outcomes was guided by a core outcome set developed by stakeholders including patients (12). We

apply rigorous methods for assessing the certainty of evidence from network meta-analyses using a

minimally contextualized approach and minimally important differences (23). Our systematic review and

network meta-analysis presents the only available evidence on the comparative effectiveness of

biologics—given the absence of trials directly comparing biologics.

Although we performed a rigorous search for eligible studies and supplemented our search with

previous systematic reviews of biologics for asthma, it is possible that we missed eligible trials.

While the GRADE framework presents a transparent system for assessing the certainty of evidence and

accounts for all factors that may bear on the certainty of evidence, its application is subjective and

others rating the certainty of evidence may come to different conclusions. Further, our assessment of

the certainty of evidence using the minimally contextualized approach required us to identify the

minimally important difference. We encourage evidence users to consider effects that their patients

would consider to be important when interpreting our results. For example, some patients may place a

high value on reductions in exacerbations and may consider a reduction in exacerbations less than 20%

to still be important.

In our network meta-analysis, we categorized different doses of the same biologic and different routes

of administration (i.e., subcutaneous vs. intravenous) in the same node. While this approach maximized

the number of patients included in each node, the effects of biologics may vary by dose and route of

administration. Most trials, however, that tested different doses and routes of administration did not

find evidence of clinically important differences in effects (54, 77).

Trials reported data on the effects of biologics between 12 and 52 weeks. The effects of biologics,

including potential adverse events, beyond these timeframes are uncertain.

We report data on adverse events that led to discontinuation. While we found biologics to be well

tolerated, serious and life-threatening adverse events are possible and were not captured by our review.

A very small proportion of patients, for example, may experience anaphylaxis—typically after the first

three doses. Because of this risk, clinicians should consider providing patients with epinephrine and

administering the first doses in a healthcare setting.

We present convincing evidence that the effects of biologics vary based on eosinophils. We show that

biologics, including tezepelumab, are probably not effective for patients with low eosinophils—a finding

that is consistent with a previous systematic review and network meta-analysis (9). There is also

inherent variability in eosinophils over time. It is possible that trials may capture patients at a random

high or low in eosinophil count. Therefore, our review may underestimate differences in effects of

biologics based on eosinophils.

Our review focuses on adults and includes limited data on the effects of biologics in children. Given the

effectiveness of these drugs in adults with eosinophilic asthma, additional clinical trials in children are

warranted. Currently, omalizumab—which we found to not be effective—is the only biologic approved

by the FDA for children under 6 years (84).

***Implications***

Our results have implications for the management of patients with severe uncontrolled asthma. Our

results strongly support the use of biologics for the treatment of patients with high eosinophils. For

patients with eosinophilic asthma, tezepelumab and dupilumab are effective at reducing exacerbations,

without important differences in the effects of the two biologics.

Our results, however, do not support the use of biologics for patients with low eosinophils. In December

2021, the FDA approved tezepelumab for patients with severe uncontrolled asthma, regardless of

eosinophil levels (83). Tezepelumab is regarded as the first biologic to reduce asthma exacerbations

consistently and significantly in a broad population of asthma patients. For patients with low

eosinophils, tezepelumab, however, did now show evidence of effectiveness. Differences between our

findings and findings reported in previous clinical trials may be due to our use of absolute effects and

minimally important differences to interpret results and the trials' emphasis on statistical significance

(73, 77). Suboptimal response in patients with low eosinophils may be related to multiple problematic

inflammatory pathways including inflammation, airflow obstruction related to airway remodeling, or

significant airways hyperresponsiveness. Other investigators have also been skeptical of the effects of

tezepelumab in patients with low eosinophils (85).

Our results suggest that clinicians should be mindful when using tezepelumab in patients with low

eosinophils given the costs and practical burdens of the drug (i.e., subcutaneous injection) and since

these patients are unlikely to derive as substantial of a benefit as patients with eosinophilic asthma.

Our results also do not support the use of omalizumab. Omalizumab was markedly less effective than

other biologics.

**Conclusion**

For patients with eosinophilic asthma, tezepelumab and dupilumab are effective at reducing

exacerbations, without important differences in the effects of the three biologics. For patients with low

eosinophils, however, biologics, including tezepelumab, probably do not prevent exacerbations or

improve asthma control or lung function.

**Tables**

**Table 1: Trial characteristics**

| Trial | Registration | Male (%) | Age | Blood eosinophil (cells/uL) | IgE (IU/mL) | Oral corticosteroids (%) | Allergic asthma (%) | Interventions |
|---|---|---|---|---|---|---|---|---|
| Ayres, 2004 | NR | 29.49 | 37.5 (omalizumab), 39.3 (standard care)§ | NR | 167 (omalizumab), NR (standard care)§ | NR | 100 | omalizumab, standard care |
| Bardelas, 2012 | NCT00267202 | 33.58 | 41.3 | NR | 182.06 | 0 | 100 | omalizumab, placebo |
| Bateman, 2017 | NCT01437735 | 42.3 | 44.9 | NR | NR | NR | 100 | fevivpiprant, placebo |
| Bel, 2014 (SIRIUS) | NCT01691508 | 45.19 | 50 | 240.22 | 115.53 | 100 | 45.92 | mepolizumab, placebo |
| Bernstein, 2020 (Trial 1) | NCT02452190 | 40.9 | 45 | 767.2 | NR | 6.5 | 67.5 | reslizumab, placebo |
| Bernstein, 2020 (Trial 2) | NCT02501629 | 34 | 54.3 | 500.1 | NR | 100 | 53 | reslizumab, placebo |
| Bjermer, 2016 | NCT01270464 | 42 | 43.9 | 613.5 | NR | 0 | NR | reslizumab (0.3mg/kg), reslizumab (3mg/kg), placebo |
| Bleecker, 2016 (SIROCCO) | NCT01928771 | 33.89 | 48.8 | 370 (placebo), 390 (benralizumab (Q4wk)), 360 (benralizumab (Q8wk))§ | NR | 16.28 | 53.65 | benralizumab (Q4w), benralizumab (Q8w), placebo |
| Boulet, 1997 | NR | 60 | 27 | NR | 410.78 | NR | 100 | omalizumab, placebo |
| Brightling, 2020 (LUSTER 1) | NCT02555683 | 35.84 | 50.36 | 320 (fevipiprant (150 mg)), 350 (fevipiprant (450)), 325 (placebo)§ | NR | NR | NR | fevipiprant (150mg), fevipiprant (450mg), placebo |
| Brightling, 2020 (LUSTER 2) | NCT02563067 | 40.75 | 50.03 | 320 (fevipiprant (150 mg)), 340 (fevipiprant (450)), 300 (placebo)§ | NR | NR | NR | fevipiprant (150mg), fevipiprant (450mg), placebo |
| Busse, 2001 | NR | 40.9 | 39.1 | NR | 179.26 | 100 | 100 | omalizumab, placebo |
| Castro, 2011 | NR | 40.5 | 45.35 | 500 | NR | 0 | 80 | omalizumab, placebo |
| Castro, 2015 (Trial 1) | NCT01287039 | 38 | 49 (placebo), 48 (reslizumab)§ | 660 | NR | 19 | NR | reslizumab, placebo |
| Castro, 2015 (Trial 2) | NCT01285323 | 36.5 | 48 (placebo), 48 (reslizumab)§ | 649 | NR | 12 | NR | reslizumab, placebo |
| Castro, 2018 (LIBERTY ASTHMA QUEST 1) | NR | 38.29 | 48 | 356.02 | 438.6 | 0 | NR | reslizumab, placebo |
| Castro, 2018 (LIBERTY ASTHMA QUEST 2) | NR | 35.85 | 47.87 | 364.46 | 426.1 | NR | NR | dupilimab, placebo |
| Castro, 2021 (ZEAL 1) | NCT03215758 | 35.8 | 47.9 | 348 | NR | NR | NR | dupilimab, placebo |
| Castro, 2021 (ZEAL 2) | NCT03226392 | 38.15 | 38.1 | 334.3 | NR | NR | NR | fevipiprant, placebo |

| Study | ID | | | | | | | Treatments |
|---|---|---|---|---|---|---|---|---|
| Chanez, 2010 | NCT00454051 | 38.7 | 47.4 | NR | 220.09 | 22.6 | 100 | fevipiprant, placebo |
| Chupp, 2017 (MUSCA) | NCT02281318 | 41.02 | 50.96 | 325.14 | NR | 23.77 | NR | omalizumab, placebo |
| Corren, 2011 | NCT00495612 | 38 | 36.5 | NR | 208.89 | NR | 100 | mepolizumab, placebo |
| Corren, 2016 | NCT01508936 | 36.1 | 44.9 | 280.2 | NR | 0 | NR | omalizumab every 2 weeks for 16 weeks, subcutaneous], placebo |
| Corren, 2017 (PATHWAY) | NCT02054130 | 34.36 | 51.55 | 370.48 | 409.96 | NR | NR | reslizumab, placebo |
| Djukanovic, 2004 | NR | 46 | 26 (omalizumab), 26 (placebo)§ | NR | 155.5 (omalizumab), 141 (placebo)§ | NR | 100 | tezepelumab (70mg), tezepelumab (210mg), tezepelumab (280mg), placebo |
| Erpenbeck, 2015 | NCT01253603 | 81.2 | 42 | NR | 166§ | 0 | 100 | omalizumab, placebo |
| Ferguson, 2017 | NCT02322775 | 39 | 49.7 | 207.5 | NR | NR | 64 | fevipiprant, placebo |
| FitzGerald, 2016 (CALIMA) | NCT01914757 | 38 | 49.2 | 363.2 | NR | 9.2 | 63.3 | benralizumab, placebo |
| Flood-Page, 2007 | NR | 44.2 | 36.31 | 365.48 | 161.5 (mepolizumab (750mg)), 203.0 (mepolizumab (250mg)), 178 (placebo)§ | NR | NR | benralizumab (Q4w), benralizumab (Q8w), placebo |
| Gevaert, 2022 (THUNDER) | NCT03681093 | 58.2 | 50.2 | NR | NR | NR | NR | mepolizumab (250mg), mepolizumab (750mg), placebo |
| Gonem, 2016 | NCT01545726 | 50.82 | 50 | 280 | 414 (fevipiprant), 388 (placebo) | 23 | NR | fevipiprant (150mg), fevipiprant (450mg), placebo |
| Haldar, 2009 | ISRCTN75169762 | 52.46 | 49.05 | 336 | 186.82 | 55 | NR | fevipiprant, placebo |
| Hanania, 2011 | NCT00314574 | 34.32 | 44.49 | NR | 176.91 | 18.75 | 100 | mepolizumab, placebo |
| Harrison, 2020 (ANDHI) | NCT03170271 | 39.18 | 52.78 | 390 (standard care), 390 (benralizumab)§ | NR | 19.66 | NR | omalizumab, standard care |
| Hayashi, 2020 | UMIN000018777 | 37.5 | 53§ | 370§ | 169§ | 18.75 | 100 | benralizumab, placebo |
| Holgate, 2004 | NR | 39.02 | 40.81 | NR | 266.26 | 0 | 100 | omalizumab, placebo |
| Humbert, 2005 (INNOVATE) | NR | 33.41 | 43.35 | NR | 193.59 | 21.72 | 100 | omalizumab, placebo |
| Kelsen, 2021 (ZENYATTA) | NCT02918019 | 33.9 | 51.9 | 246.7 | NR | NR | NR | omalizumab, placebo |
| Kopp, 2018 | EUDRACT: 2005-003860-47 | 56.43 | 30 (omalizumab), 33 (placebo)§ | NR | 139.25 | NR | 100 | astegolimab (70mg, Q4w), astegolimab (120mg, Q4w), astegolimab (490mg, Q4w), |

| Study | NCT | | | | | | | Intervention |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | placebo |
| Li, 2016 | NCT01202903 | 46.1 | 46.5 | NR | 275.4 | NR | 100 | omalizumab (dose not specified, every 2 or 4 weeks for 32 weeks, subcutaneous], placebo |
| Menzies-Gow, 2021 (NAVIGATOR) | NCT03347279 | 36.54 | 49.5 | 340 | 565 | 9.44 | 68.46 | omalizumab, placebo |
| Nair, 2017 (ZONDA) | NCT02075255 | 38.64 | 50.99 | 535 (placebo), 462 (benralizumab (Q4w)), 437 (benralizumab (Q8w))§ | NR | 100 | NR | tezepelumab, placebo |
| Nowak, 2014 | NCT00768079 | 30 | 36.19 | 260 | NR | 100 | NR | benralizumab (Q4w), benralizumab (Q8w), placebo |
| Ohta, 2009 | NCT00232050. | 45.71 | 49.01 | NR | 253.75 | 9.52 | 100 | benralizumab (0.3mg/kg), benralizumab (1mg/kg, one dose, intravenous], placebo |
| Ortega, 2014 | NCT01691521 | 42.88 | 50 | 296.63 | 159.95 | 25 | 48.78 | omalizumab, placebo |
| Panettieri, 2018 (STRATOS 1) | NCT02161757 | 33.61 | 50.64 | 286 | NR | 0 | NR | mepolizumab (75mg), mepolizumab (100mg), placebo |
| Panettieri, 2018 (STRATOS 2) | NCT02194699 | 32.38 | 47.65 | 277.53 | NR | 0 | NR | tralokinumab (Q2w), tralokinumab (Q4w), placebo |
| Panettieri, 2020 (SOLANA) | NCT02869438 | 32.5 | 51.4 | 438.05 | NR | 6.9 | NR | Tralokinumab, placebo |
| Park, 2016 | NCT01691508 | 36.89 | 52.72 | 682.91 | NR | NR | NR | benralizumab, placebo |
| Pavord, 2012 (DREAM) | NCT01000506 | 62.9 | 48.6 | 252.6 | NR | 30.4 | 50.5 | benralizumab (2mg), benralizumab (20mg), benralizumab (100mg), placebo |
| Pineros, 2018 (MATERIAL) | NCT01520051 | 25 | 23.5 | 350 | 303.12 | 0 | 100 | mepolizumab (75mg), mepolizumab (250mg), mepolizumab (750mg), placebo |
| Piper, 2013 | NCT00873860 | 40.21 | 47.32 | NR | NR | 4.64 | 52 | mepolizumab, placebo |
| Rabe, 2018 (LIBERTY ASTHMA VENTURE) | NCT02528214 | 39.52 | 51.3 | 357 | NR | 100 | 56.67 | tralokinumab (150mg), tralokinumab (300mg), tralokinumab (600mg), placebo |
| Rubin, 2012 (QUALITX) | NR | 23.28 | 44.26 | NR | 228.76 | NR | 24.14 | dupilimab, placebo |
| Russell, 2018 (MESOS) | NCT02449473 | 45.57 | 48.62 | 284.81 | 476.28 | NR | NR | omalizumab, control (none) |
| Soler, 2001 | NR | 49.1 | 39.5 | NR | 214.38 | 0 | 100 | tralokinumab, placebo |
| Sverrild, 2021 (UPSTREAM) | NCT02698501 | 42 | 41 | 214 | 102 | 0 | 65 | omalizumab, placebo |
| Vignola, 2004 (SOLAR) | NR | 44.94 | 38.39 | NR | NR | NR | 100 | tezepelumab, placebo |
| Wechsler, 2021 | NCT03387852 | 36 | 49.1 | 372 | 419.3 | NR | 85 | omalizumab, placebo |
| Wechsler, 2022 (SOURCE) | NCT03406078 | 37 | 53.4 | 299.8 | 299.8 | 100 | 57 | itepekimab, itepekimab/dupilumab, dupilumab, placebo |

| Wenzel, 2013 | NCT01312961 | 50 | 39.7 | 510 | 676.2 | NR | NR | tezepelumab, placebo |
| Wenzel, 2016 | NCT01854047 | 37 | 48.6 | 347.46 | 435.05 | 0 | NR | dupilumab, placebo |
| Zielen, 2011 | NR | 55.8 | 33.12 | NR | 662.92 | NR | 100 | dupilumab (200mg, Q4w), dupilumab (300mg, Q4w), dupilumab (200mg, Q2w), dupilumab (300mg, Q2w), placebo |

IgE: Immunoglobulin E

Data presented as mean unless specified with §. Data with § is median.

**Table 2**. Summary of findings table for network estimates presented in absolute risk difference per 1000 patients.

**GRADE recommendation**

| Certainty | | | |
|---|---|---|---|
| High certainty | Definitely more beneficial than standard care | Definitely more harmful than standard care | Definitely no different than standard care |
| Moderate certainty | Probably more beneficial than standard care | Probably more harmful than standard care | Probably no different than standard care |
| Low certainty | May be more beneficial than standard care | May be more harmful than standard care | May be no different than standard care |
| Very low certainty | We are very uncertain | We are very uncertain | We are very uncertain |

| Drug | Asthma exacerbations | | ACQ | | FEV1 (L) | | Hospital admissions | Corticosteroid sparing | ADEL |
|---|---|---|---|---|---|---|---|---|---|
| *Eosinophils* | ≥ 300 | < 300 | ≥ 300 | < 300 | ≥ 300 | < 300 | NA | NA | NA |
| *Baseline risk* | 470 per 1000 | | NA | | NA | | 137 per 1000 | 560 per 1000 | 19 per 1000 |
| *MCID/MID* | 20% | | -0.5 | | 0.1 L | | 5% | 20% | 10% |
| Tezepelumab | -329 (-366.6 to -272.6) | -173.9 (-277.3 to -23.5)‡ | -0.4 (-0.61 to -0.19)‡ | -0.23 (-0.36 to -0.09) | 0.24 (0.16 to 0.32) | 0.1 (0 to 0.19)¶ | -110.97 (-120.56 to -94.53)‡ | 33.6 (-72.8 to 168)¶ | -6.08 (-12.54 to 6.65) |
| Dupilumab | -319.6 (-357.2 to -272.6) | -112.8 (-225.6 to 51.7)‡ | -0.73 (-0.98 to -0.48)‡ | -0.2 (-0.42 to 0.02) | 0.25 (0.21 to 0.29) | 0.1 (0 to 0.2)¶ | -97.27 (-124.67 to -4.11)‡ | 274.4 (123.2 to 464.8)¶ | 0.57 (-10.26 to 24.7) |
| Mepolizumab | -211.5 (-258.5 to -155.1)‡ | | -0.33 (-0.51 to -0.15)‡ | 0.49 (0.01 to 0.97)‡ | 0.1 (0.04 to 0.15)‡ | | | 341.6 (39.2 to 789.6)‡ | -6.65 (-12.16 to 3.04) |
| Resliuzmab | -230.3 (-282 to -164.5)‡ | 371.3 (-188 to 2002.2)¶ | -0.28 (-0.44 to -0.11) | 0.12 (-0.09 to 0.33) | 0.19 (0.12 to 0.25) | 0.09 (-0.04 to 0.22)¶ | | 128.8 (-84 to 436.8)¶ | -6.65 (-11.21 to 0.38) |
| Benralizumab | -230.3 (-277.3 to -173.9)‡ | -145.7 (-263.2 to 37.6)‡ | -0.3 (-0.44 to -0.16) | -0.23 (-0.41 to -0.06) | 0.14 (0.11 to 0.18)‡ | 0.04 (-0.05 to 0.13)‡ | -17.81 (-41.1 to 10.96) | 431.2 (162.4 to 800.8)‡ | 12.35 (-3.99 to 46.55) |
| Astegolimab | -150.4 (-314.9 to 178.6) ¶ | -126.9 (-291.4 to 188) | | | | | | | |
| Fevipiprant | -89.3 (-183.3 to 42.3) | | -0.15 (-0.35 to 0.05) | | 0.05 (-0.01 to 0.12)‡ | | | | 0.19 (-6.65 to 10.83) |
| Tralokinumab | -70.5 (-178.6 to 75.2) | -89.3 (-244.4 to 173.9)‡ | -0.52 (-0.94 to -0.1)¶ | | | | -32.88 (-64.39 to 12.33)‡ | | 32.3 (8.55 to 76) |

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Itepekimab | | | -0.46 (-0.8 to -0.12)‡* | 0.18 (0 to 0.36)‡ | 0.09 (-0.1 to 0.28)¶ | | | | |
| Itepekimab/dupilumab | | | -0.36 (-0.7 to -0.02)‡* | 0.15 (-0.05 to 0.34)¶ | 0.05 (-0.14 to 0.24)¶ | | | | |
| Omalizumab | -188 (-235 to 136.3)‡* | | -0.25 (-0.5 to 0.01)‡* | | 0.09 (0.02 to 0.16)‡* | | -84.94 (-105.49 to -47.95)‡ | 179.2 (84 to 285.6)‡ | 3.8 (-3.8 to 15.39)‡ |
| *I²* | *36.30%* | *58%* | *50.10%* | *0%* | *38.80%* | *54.90%* | *25.20%* | *0%* | *5.70%* |

Note: CI = confidence interval, GRADE = Grading of Recommendations, Assessment, Development and Evaluation.

*No subgroup available, data from entire network.

All included estimates are network estimates. Negative values indicate fewer events and positive values indicate more events. Each node estimate is compared against placebo or standard care. The comparative effectiveness of a treatment on an outcome versus another treatment can be assessed by comparing respective cells. If the network estimate is not presented owing to lower certainty of the evidence, then direct comparisons need to be made using the network estimates provided in high certainty ( very confident that true effect lies close to that of effect estimate), moderate certainty (moderately confident in effect estimate; the true effect is likely to be close to effect estimate, but there is a possibility that it is substantially different), low certainty (confidence in the effect estimate is limited; true effect may be substantially different from the effect estimate) or very low certainty: (very little confidence in the effect estimate; true effect is likely to be substantially different from the effect estimate).

‡GRADE rating = imprecision.

¶GRADE rating = twice for imprecision.

††GRADE rating = inconsistency.

## References

1.    Global Asthma Network. Global Asthma Network Global Asthma Report 2018 www.globalasthmareport.org/ Date last updated: January 2018. Date last accessed: January 17, 2020.

2.    Global Initiative for Asthma. (2002). Global strategy for asthma management and prevention. Bethesda, Md.: National Institutes of Health, National Heart, Lung, and Blood Institute.

3.    Mauer Y, Taliercio RM. Managing adult asthma: The 2019 GINA guidelines. Cleve Clin J Med. 2020;87(9):569-75.

4.    Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. European Respiratory Journal. 2020;56(5).

5.    Sadeghirad B, Foroutan F, Zoratti MJ, Busse JW, Brignardello-Petersen R, Guyatt G, et al. Theory and practice of Bayesian and frequentist frameworks for network meta-analysis. BMJ Evid Based Med. 2022.

6.    Hutton B, Catalá-López F, Moher D. [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA]. Med Clin (Barc). 2016;147(6):262-6.

7.    Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014(1):Cd003559.

8.    Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9(9):Cd010834.

9.    Menzies-Gow A, Steenkamp J, Singh S, Erhardt W, Rowell J, Rane P, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679-90.

10.   Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179.

11.   Edris A, Lahousse L. Monoclonal antibodies in type 2 asthma: an updated network meta-analysis. Minerva Med. 2021;112(5):573-81.

12.   Tejwani V, Chang HY, Tran AP, Naber JA, Gutzwiller FS, Winders TA, et al. A multistakeholder Delphi consensus core outcome set for clinical trials in moderate-to-severe asthma (coreASTHMA). Ann Allergy Asthma Immunol. 2021;127(1):116-22.e7.

13.   Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.

14.   Pitre T, Van Alstine R, Chick G, Leung G, Mikhail D, Cusano E, et al. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. Cmaj. 2022;194(28):E969-e80.

15.   Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.

16.   van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods. 2016;7(1):80-93.

17.   Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3(2):161-76.

18.   Rücker G, Schwarzer G, Krahn U, König J, Schwarzer MG. Package 'netmeta'. Network Meta-Analysis using Frequentist Methods (Version 07-0). 2015.

19.   Schwarzer G. meta: An R package for meta-analysis. R news. 2007;7(3):40-5.

20.   Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS one. 2013;8(10):e76654.

21.   Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36-44.

22.      Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging
consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-6.
23.      Brignardello-Petersen R, Florez ID, Izcovich A, Santesso N, Hazlewood G, Alhazanni W, et al.
GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised
framework. Bmj. 2020;371:m3900.
24.      Rogliani P, Calzetta L. Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on
Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON
Studies. J Exp Pharmacol. 2022;14:1-5.
25.      Bonini M, Di Paolo M, Bagnasco D, Baiardini I, Braido F, Caminati M, et al. Minimal clinically
important difference for asthma endpoints: an expert consensus report. Eur Respir Rev. 2020;29(156).
26.      Tepper RS, Wise RS, Covar R, Irvin CG, Kercsmar CM, Kraft M, et al. Asthma outcomes:
pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 Suppl):S65-87.
27.      Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26:
informative statements to communicate the findings of systematic reviews of interventions. J Clin
Epidemiol. 2020;119:126-35.
28.      Panettieri RA, Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for
severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-
controlled, phase 3 clinical trials. Lancet respiratory medicine. 2018;6(7):511.
29.      Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, et al. Effectiveness of fevipiprant in
reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3
randomised controlled trials. Lancet respiratory medicine. 2021;9(1):43.
30.      Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and
tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic
asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709.
31.      Gevaert P, Bachert C, Maspero JF, Cuevas M, Steele D, Acharya S, et al. Phase 3b randomized
controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER). Journal of Allergy
and Clinical Immunology. 2022.
32.      Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral Glucocorticoid-Sparing
Effect of Benralizumab in Severe Asthma. New England journal of medicine. 2017;376(25):2448.
33.      Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-
immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe)
allergic asthma. Allergy. 2004;59(7):701.
34.      Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-
controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with
persistent allergic asthma. Journal of asthma. 2012;49(2):144.
35.      Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and
impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms
for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised,
controlled, phase 3b trial. Lancet respiratory medicine. 2021;9(3):260.
36.      Bateman ED, Guerreros AG, Brockhaus F, Holzhauer B, Pethe A, Kay RA, et al. Fevipiprant, an
oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled
corticosteroids. The european respiratory journal. 2017;50(2).
37.      Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, et al. Effect of fixed-dose
subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and
corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3,
randomised, double-blind, placebo-controlled trials. Lancet respiratory medicine. 2020;8(5):461.

38.　　Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, et al.
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet respiratory medicine. 2017;5(7):568.

39.　　Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately
Controlled Asthma With Elevated Blood Eosinophil Levels: a Randomized Phase 3 Study. Chest.
2016;150(4):789.

40.　　Boulet LP, Chapman KR, ocirc, eacute, Kalra S, Bhagat R, et al. Inhibitory effects of an anti-IgE
antibody E25 on allergen-induced early asthmatic response. American journal of respiratory and critical
care medicine. 1997;155(6):1835.

41.　　Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. American Journal
of Respiratory and Critical Care Medicine. 2001;164(8 II):S12-S7.

42.　　FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-
interleukin-5 receptor &agr; monoclonal antibody, as add-on treatment for patients with severe,
uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 2016;388(10056):2128.

43.　　Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for
inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre,
parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet respiratory medicine.
2015;3(5):355.

44.　　Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly
controlled, eosinophilic asthma: a randomized, placebo-controlled study. American journal of
respiratory and critical care medicine. 2011;184(10):1125.

45.　　Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, et al. Omalizumab-induced
decrease of FcepsilonRI expression in patients with severe allergic asthma. Respiratory Medicine.
2010;104(11):1608-17.

46.　　Corren J, Wood RA, Patel D, Zhu J, Yegin A, Dhillon G, et al. Effects of omalizumab on changes in
pulmonary function induced by controlled cat room challenge. Journal of allergy and clinical
immunology. 2011;127(2):398.

47.　　Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in Patients With
Poorly Controlled Asthma: effects Across a Broad Range of Eosinophil Counts. Chest. 2016;150(4):799.

48.　　Djukanovic R, Wilson SJ, Kraft M, Jarjour N, Steel M, Chung KF, et al. Effect of treatment with
anti-IgE antibody (Omalizumab) on airway inflammation in mild atopic asthma. American thoracic
society 99th international conference. 2003:C082.

49.　　Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe
eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (london,
england). 2012;380(9842):651.

50.　　Erpenbeck VJ, Popov TA, Miller D, Weinstein SF, Spector S, Magnusson B, et al. The oral CRTh2
antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulmonary
pharmacology & therapeutics. 2016;39:54.

51.　　Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, et al. Efficacy and Safety of
Itepekimab in Patients with Moderate-to-Severe Asthma. New England journal of medicine.
2021;385(18):1656.

52.　　Panettieri RA, Welte T, Shenoy KV, Korn S, Jandl M, Kerwin EM, et al. Onset of effect, changes in
airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab
for patients with severe eosinophilic asthma: phase iiib randomized, controlled trial (SOLANA). Journal
of asthma and allergy. 2020;13:115.

53.  Sol, egrave, r M, Matz J, Townley R, Buhl R, et al. The anti-IgE antibody omalizumab reduces
exacerbations and steroid requirement in allergic asthmatics. The european respiratory journal.
2001;18(2):254.

54.  Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety
in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled
corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal
phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44.

55.  Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent
asthma with elevated eosinophil levels. New England journal of medicine. 2013;368(26):2455.

56.  Castro M, Kerwin E, Miller D, Pedinoff A, Sher L, Cardenas P, et al. Efficacy and safety of
fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind,
placebo-controlled trials (ZEAL-1 and ZEAL-2). EClinicalMedicine. 2021;35.

57.  Zielen S, Lieb A, De La Motte S, Wagner F, De Monchy J, Fuhr R, et al. Omalizumab protects
against allergen-induced bronchoconstriction in allergic (Immunoglobulin E-mediated) Asthma.
International archives of allergy and immunology. 2013;160(1):102.

58.  Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to
evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American
journal of respiratory and critical care medicine. 2007;176(11):1062.

59.  Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, et al. Fevipiprant, a
prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre,
randomised, double-blind, parallel-group, placebo-controlled trial. Lancet respiratory medicine.
2016;4(9):699.

60.  Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and
exacerbations of refractory eosinophilic asthma. New England journal of medicine. 2009;360(10):973.

61.  Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe
allergic asthma inadequately controlled with standard therapy: a randomized trial. Annals of internal
medicine. 2011;154(9):573.

62.  Hayashi H, Fukutomi Y, Mitsui C, Kajiwara K, Watai K, Kamide Y, et al. Omalizumab for Aspirin
Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A
Randomized Controlled Trial. American journal of respiratory and critical care medicine.
2020;201(12):1488.

63.  Holgate ST, Chuchalin AG, eacute, bert J, ouml, tvall J, et al. Efficacy and safety of a recombinant
anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and experimental
allergy. 2004;34(4):632.

64.  Humbert M, Beasley R, Ayres J, Slavin R, eacute, bert J, et al. Benefits of omalizumab as add-on
therapy in patients with severe persistent asthma who are inadequately controlled despite best
available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309.

65.  Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of
omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal
allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clinical and experimental allergy.
2009;39(2):271.

66.  Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, et al. Omalizumab improves quality of life and
asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study.
Allergy, asthma & immunology research. 2016;8(4):319.

67.  Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and
Safety in Moderate-to-Severe Uncontrolled Asthma. New England journal of medicine.
2018;378(26):2486.

68. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of
Dupilumab in Glucocorticoid-Dependent Severe Asthma. New England journal of medicine.
2018;378(26):2475.
69. Sabogal P, ntilde, eros YS, Bal SM, van de Pol MA, Dierdorp BS, et al. Anti-IL-5 in Mild Asthma
Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-
controlled, Double-Blind Study. American journal of respiratory and critical care medicine.
2019;199(4):508.
70. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab
treatment in patients with severe eosinophilic asthma. New England journal of medicine.
2014;371(13):1198.
71. Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, et al. Effect of
tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation
in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-
controlled phase 2 trial. Lancet respiratory medicine. 2018;6(7):499.
72. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of
mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe
eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group,
multicentre, phase 3b trial. Lancet respiratory medicine. 2017;5(5):390.
73. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in
Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384(19):1800-9.
74. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M. Efficacy and safety of omalizumab in an Asian
population with moderate-to-severe persistent asthma. Respirology. 2009;14(8):1156-65.
75. Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A Phase 2a Study of Benralizumab
for Patients with Eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol.
2016;169(3):135-45.
76. Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of
benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. American
journal of emergency medicine. 2015;33(1):14.
77. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in Adults with
Uncontrolled Asthma. N Engl J Med. 2017;377(10):936-46.
78. Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, et al. Effect of
omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian
study (QUALITX). Journal of asthma. 2012;49(3):288.
79. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study
of tralokinumab in moderate-to-severe asthma. The european respiratory journal. 2013;41(2):330.
80. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of
benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids
and long-acting &bgr;2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Lancet (london, england). 2016;388(10056):2115.
81. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-
sparing effect of mepolizumab in eosinophilic asthma. New England journal of medicine.
2014;371(13):1189.
82. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a
questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902-7.
83. Tan LD, Nguyen N, Alismail A, Castro M. Management of Uncontrolled Asthma: A Framework for
Novel and Legacy Biologic Treatments. J Asthma Allergy. 2022;15:875-83.

84. Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for Severe Asthma: Treatment-
Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol Pract. 2019;7(5):1379-
92.
85. Adatia A, Wahab M, Satia I. Is tezepelumab more than just an anti-eosinophil drug? Eur Respir J.
2022;59(1).

**Figure 1.** Network diagrams for acute exacerbations with high and low eosinophils. Each node

represents a drug or drug combination that has been tested in trials; the size of the nodes is

proportional to the number of patients that have received that drug or drug combination; and the

thickness of the connecting lines is proportional to the number of trials.

**Figure 2.** Forest plots for exacerbations with high and low eosinophils .

A: Exacerbations among patients with eosinophilic asthma

B: Exacerbations among patients with low eosinophils

**A: Exacerbations among patients with eosinophilic asthma**

| Drug | | Risk Ratio with 95% CI |
|------|---|------------------------|
| Astegolimab | | 0.68 [ 0.33, 1.38] |
| Benralizumab | | 0.51 [ 0.41, 0.63] |
| Dupilumab | | 0.32 [ 0.24, 0.42] |
| Fevipiprant | | 0.81 [ 0.61, 1.09] |
| Mepolizumab | | 0.52 [ 0.43, 0.64] |
| Reslizumab | | 0.51 [ 0.40, 0.65] |
| Tezepelumab | | 0.30 [ 0.22, 0.42] |
| Tralokinumab | | 0.85 [ 0.62, 1.16] |
| Overall | | |

Heterogeneity: $\tau^2 = 0.0244$, $I^2 = 36.3\%$

Random-effects REML model

**B: Exacerbations among patients with low eosinophils**

| Drug | | Risk Ratio with 95% CI |
|------|---|------------------------|
| Astegolimab | | 0.73 [ 0.38, 1.40] |
| Benralizumab | | 0.69 [ 0.44, 1.08] |
| Dupilumab | | 0.76 [ 0.52, 1.11] |
| Reslizumab | | 1.78 [ 0.59, 5.33] |
| Tezepelumab | | 0.62 [ 0.41, 0.95] |
| Tralokinumab | | 0.82 [ 0.48, 1.38] |
| Overall | | |

Heterogeneity: $\tau^2 = 0.0904$, $I^2 = 58.00$

Random-effects REML model